
3C Therapeutics is a Vancouver-based biotechnology company developing next-generation Degrader-Antibody Conjugates (DACs) — a new class of targeted therapeutics that harness the precision of antibodies to deliver protein degraders directly to diseased cells. Our proprietary TriCore™ platform enables modular design and rapid optimization of DACs across multiple disease areas, extending the reach of targeted protein degradation beyond oncology. By integrating deep expertise in antibody engineering, linker chemistry, and protein degradation biology, 3C is building a versatile pipeline of…
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.